Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels

British Journal of Cancer

Volumn 99, Issue 10, 2008, Pages 1743-1747

  Jesser, C ^a,b   Mucci, L ^a,b,c   Farmer, D ^d   Moon, C ^d   Li, H ^b   Gaziano, J M ^a,b   Stampfer, M ^a,b,c   Ma, J ^b,c   Kantoff, P ^c,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; ARE1 158 G A polymorphism (rs266882); Physicians' Health Study; Prostate cancer; PSA gene

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALLELE; ANDROGEN RESPONSE ELEMENT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; HORMONE RESPONSIVE ELEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PSA GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 55949088436     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604690     Document Type: Article

References (28)

1. (1989) Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 321: 129-135
2. Binnie MC, Alexander FE, Heald C, Habib FK (2005) Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 63: 309-315
3. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566
4. Chiang CH, Chen KK, Chang LS, Hong CJ (2004) The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J Urol 171: 1529-1532
5. Cicek MS, Liu X, Casey G, Witte JS (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 14: 2173-2177
6. Cohen P, Peehl DM, Graves HC, Rosenfeld RG (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142: 407-415
7. Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF (2005) Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 202: 361-370
8. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118-1126
9. Gann PH, Hennekens CH, Stampfer MJ (1995) A Prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 273(4): 289-294
10. Gann PH, Ma J, Catalona WJ, Stampfer MJ (2002) Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 167: 2427-2434
11. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320-3323
12. Gsur A, Preyer M, Haidinger G, Zidek T, Madersbacher S, Schatzl G, Marberger M, Vutuc C, Micksche M (2002) Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23: 1647-1651
13. Janne OA, Palvimo JJ, Kallio P, Mehto M (1993) Androgen receptor and mechanism of androgen action. Ann Med 25: 83-89
14. Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, Spurdle AB, Morris CP, Harris J, Clements JA (2007) PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 28: 1032-1039
15. Massague J (2008) TGFbeta in Cancer. Cell 134: 215-230
16. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Carvalho R, Lopes C (2002) Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 53: 88-94
17. Rao A, Chang BL, Hawkins G, Hu JJ, Rosser CJ, Hall MC, Meyers DA, Xu J, Cramer SD (2003) Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 61: 864-869
18. Rao A, Cramer SD (1999) Identification of a polymorphism in the ARE1 region of the PSA promoter (abstract). Cancer Res 40: 60
19. Salinas CA, Austin MA, Ostrander EO, Stanford JL (2005) Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 65: 58-65
20. Schatzl G, Marberger M, Remzi M, Grosser P, Unterlechner J, Haidinger G, Zidek T, Preyer M, Micksche M, Gsur A (2005) Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer. Urology 65: 1141-1145
21. Severi G, Hayes VM, Neufing P, Padilla EJ, Tilley WD, Eggleton SA, Morris HA, English DR, Southey MC, Hopper JL, Sutherland RL, Boyle P, Giles GG (2006) Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev 15: 1142-1147
22. Sieh W, Edwards KL, Fitzpatrick AL, Srinouanprachanh SL, Farin FM, Monks SA, Kronmal RA, Eaton DL (2006) Genetic susceptibility to prostate cancer: prostate-specific antigen and its interaction with the androgen receptor (United States). Cancer Causes Control 17: 187-197
23. StataCorp (2003) Statistical Software: Release 8.0. College Station, TX: Stata Corporation
24. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910-1917
25. Wang LZ, Sato K, Tsuchiya N, Yu JG, Ohyama C, Satoh S, Habuchi T, Ogawa O, Kato T (2003) Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett 202: 53-59
26. Xu J, Meyers DA, Sterling DA, Zheng SL, Catalona WJ, Cramer SD, Bleecker ER, Ohar J (2002) Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 11: 664-669
27. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA (2000) Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60: 839-841
28. Xue WM, Coetzee GA, Ross RK, Irvine R, Kolonel L, Henderson BE, Ingles SA (2001) Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 10: 575-579